Contribution of IL-38 in Lung Immunity during Pseudomonas Aeruginosa-induced Pneumonia
- PMID: 35583912
- DOI: 10.1097/SHK.0000000000001919
Contribution of IL-38 in Lung Immunity during Pseudomonas Aeruginosa-induced Pneumonia
Abstract
Objective: Interleukin-38 (IL-38), a new type of cytokine, is involved in processes such as tissue repair, inflammatory response, and immune response. However, its function in pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa) is still unclear.
Methods: In this study, we detected circulating IL-38 and cytokines such as IL-1β, IL-6, IL-17A, TNF-α, IL-8, and IL-10 in adults affected by early stage pneumonia caused by P. aeruginosa. Collected clinical data of these patients, such as the APACHE II score, levels of PCT, and oxygenation index when they entering the ICU. Using P. aeruginosa-induced pneumonia WT murine model to evaluate the effect of IL-38 on Treg differentiation, cell apoptosis, survival, tissue damage, inflammation, and bacterial removal.
Results: In clinical research, although IL-38 is significantly increased during the early stages of clinical P. aeruginosa pneumonia, the concentration of IL-38 in the serum of patients who died with P. aeruginosa pneumonia was relatively lower than that of surviving patients. It reveals IL-38 may insufficiently secreted in patients who died with P. aeruginosa pneumonia. Besides, the serum IL-38 level of patients with P. aeruginosa pneumonia on the day of admission to the ICU showed significantly positive correlations with IL-10 and the PaO2/FiO2 ratio but negative correlations with IL-1β, IL-6, IL-8, IL-17, TNF-α, APACHE II score, and PCT In summary, IL-38 might be a molecule for adjuvant therapy in P. aeruginosa pneumonia. In experimental animal models, first recombinant IL-38 improved survival, whereas anti-IL-38 antibody reduced survival in the experimental pneumonia murine model. Secondly, IL-38 exposure reduced the inflammatory response, as suggested by the lung injury, and reduced cytokine levels (IL-1β, IL-6, IL- 17A, TNF-α, and IL-8, but not IL-10). It also increased bacterial clearance and reduced cell apoptosis in the lungs. Furthermore, IL-38 was shown to reduce TBK1 expression in vitro when naive CD4+ T lymphocytes were differentiated to Tregs and played a protective role in P. aeruginosa pneumonia.
Conclusions: To summarize, the above findings provide additional insights into the mechanism of IL-38 in the treatment of P. aeruginosa pneumonia.
Copyright © 2022 by the Shock Society.
Conflict of interest statement
The authors report no conflicts of interest.
Similar articles
-
Interleukin-22 regulates interferon lambda expression in a mice model of pseudomonas aeruginosa pneumonia.Mol Immunol. 2020 Feb;118:52-59. doi: 10.1016/j.molimm.2019.12.003. Epub 2019 Dec 16. Mol Immunol. 2020. PMID: 31855807
-
Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia.J Leukoc Biol. 2017 Feb;101(2):543-554. doi: 10.1189/jlb.4A1215-581R. Epub 2016 Sep 14. J Leukoc Biol. 2017. PMID: 27630218 Free PMC article.
-
Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa.Clin Exp Immunol. 2000 Oct;122(1):67-71. doi: 10.1046/j.1365-2249.2000.01343.x. Clin Exp Immunol. 2000. PMID: 11012620 Free PMC article.
-
The role of IL-1β in Pseudomonas aeruginosa in lung infection.Cell Tissue Res. 2016 May;364(2):225-9. doi: 10.1007/s00441-016-2387-9. Epub 2016 Mar 17. Cell Tissue Res. 2016. PMID: 26984603 Review.
-
Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.Behring Inst Mitt. 1997 Feb;(98):269-73. Behring Inst Mitt. 1997. PMID: 9382750 Review.
Cited by
-
Emerging functions and therapeutic targets of IL-38 in central nervous system diseases.CNS Neurosci Ther. 2024 Feb;30(2):e14550. doi: 10.1111/cns.14550. CNS Neurosci Ther. 2024. PMID: 38334236 Free PMC article. Review.
-
Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.Int J Mol Sci. 2021 Nov 21;22(22):12552. doi: 10.3390/ijms222212552. Int J Mol Sci. 2021. PMID: 34830435 Free PMC article.
-
Changes and Clinical Value of Serum miR-24 and miR-223 Levels in Patients with Severe Pneumonia.Int J Gen Med. 2023 Aug 28;16:3797-3804. doi: 10.2147/IJGM.S411966. eCollection 2023. Int J Gen Med. 2023. PMID: 37662504 Free PMC article.
References
-
- Pappas G, Saplaoura K, Falagas ME. Current treatment of pseudomonal infections in the elderly. Drugs Aging 26 (5):363–379, 2009.
-
- Jara MC, Frediani AV, Zehetmeyer FK, Bruhn FRP, Muller MR, Miller RG, Nascente PDS. Multidrug-resistant hospital bacteria: epidemiological factors and susceptibility profile. Microb Drug Resist 27 (3):433–440, 2021.
-
- Omar T, Ziltener P, Chamberlain E, Cheng Z, Johnston B. Mice lacking gammadelta T cells exhibit impaired clearance of pseudomonas aeruginosa lung infection and excessive production of inflammatory cytokines. Infect Immunity 88 (6):111, 2020.
-
- Lynch JP 3rd. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 119: ((2 Suppl)): 373S–384S, 2001.
-
- Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context 7:212527, 2018.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous